Welcome to our dedicated page for Veradigm SEC filings (Ticker: MDRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Veradigm Inc. SEC filings document the company’s healthcare technology business, OTC-traded common stock and formal disclosures around financial reporting, governance and capital structure. Recent filings include Current Reports on Form 8-K covering leadership appointments, preliminary financial information, material agreements and amendments to the company’s stockholder rights plan.
The filing record also includes late-filing notices for annual reports, disclosures about financial reporting and internal-control matters, board-observer and stockholder-agreement arrangements, and the conclusion of an SEC investigation without a recommended enforcement action. These filings record Veradigm’s public-company status, common stock trading symbol MDRX, rights-plan mechanics and governance changes while the company works through delayed periodic reporting.
Rodriguez Susan reported acquisition or exercise transactions in this Form 4 filing.
Veradigm Inc. director Susan Rodriguez received a grant of 42,507 shares of Common Stock in the form of Restricted Stock Units on June 1, 2026 under the Veradigm Inc. Amended and Restated 2024 Stock Incentive Plan. The award vests 100% on the first anniversary of the grant date. After this grant, she directly holds a total of 131,125 shares of Veradigm common stock.
Veradigm Inc. director Lou Silverman reported receiving an equity grant of 42,507 shares of common stock-equivalent awards. These were granted on June 1, 2026 as Restricted Stock Units under the Veradigm Inc. Amended and Restated 2024 Stock Incentive Plan.
The RSU grant vests 100% on the first anniversary of the June 1, 2026 grant date, meaning the award must vest before the shares are fully earned. After this compensation-related acquisition, Silverman directly holds a total of 99,131 shares of Veradigm common stock.
Greyenbuhl Christian reported acquisition or exercise transactions in this Form 4 filing.
Veradigm Inc. reported that Chief Financial Officer Christian Greyenbuhl received an equity award in the form of restricted stock units. He was granted 318,809 shares of Common Stock on June 1, 2026 at a stated price of $0.00 per share, reflecting a compensation grant rather than a market purchase.
According to the footnote, the award consists of Restricted Stock Units granted under the Veradigm Inc. 2019 Stock Incentive Plan. The grant vests in four equal installments, with 1/4 of the units vesting on each of the first four anniversaries of the Grant Date. After this award, Greyenbuhl directly holds 318,809 shares reported in this filing.
Veradigm Inc. director David B. Stevens received a grant of 42,507 Restricted Stock Units (RSUs) on June 1, 2026 under the company’s 2024 Stock Incentive Plan. On the first anniversary of the grant date, all RSNs convert into an equal number of Deferred Stock Units. These Deferred Stock Units will be settled in common shares on the tenth business day of January following the calendar year in which he ceases to be a director. After this award, Stevens directly holds 163,509 shares.
Veradigm Inc. Chief Financial Officer Christian Greyenbuhl filed an initial Form 3 ownership report for the company. The filing shows he holds no shares of Veradigm common stock directly following this reporting date, and it does not record any recent purchase or sale transactions.
Veradigm Inc. entered into a Consulting Agreement with former interim CFO Leland Westerfield and Wilcox Capital LLC, effective June 1, 2026. The contractor will act as a Strategic Financial Advisor through March 31, 2027, helping with the CFO transition, SEC reporting and addressing material weaknesses in internal controls.
The company will pay a consulting fee of $45,937.50 per month for ten months, with the final two payments contingent on Westerfield signing and not revoking a general release of claims. Veradigm will also grant restricted stock units valued at $100,000 after it files its 2023 and 2024 Form 10-Ks, with those units vesting on March 31, 2027.
Veradigm Inc. files an annual report for the year ended December 31, 2024 that also provides expanded disclosures for 2023 in lieu of separate annual and quarterly reports. The company has undergone significant restatement work, internal control remediation and governance changes following earlier accounting issues.
Veradigm remains focused on healthcare technology and analytics across Provider, Payer and Life Science segments, emphasizing EHRs, revenue cycle management, payer analytics and real‑world data offerings. Recent developments include new board members, leadership changes, expanded equity incentive capacity, a new $100 million credit facility and full repayment of its 0.875% convertible notes due 2027, alongside ongoing remediation of material weaknesses and litigation related to prior periods.
MDRX: Two Seas Capital reports 8,943,265 shares (Common Stock) beneficially owned as of March 31, 2026. The Schedule 13G/A states that Two Seas Capital LP, Two Seas Capital GP LLC and Sina Toussi each may be deemed to have sole voting and dispositive power over 8,943,265 shares, representing 8.2% of the class.
The filing says the percent is calculated using 108,800,000 shares outstanding as of December 31, 2025, cited from an Exhibit to the issuer's prior Form 8-K. The Reporting Persons list their principal business address in Rye, New York.
Veradigm Inc. Schedule 13G/A: a group of Toronto-Dominion entities reports beneficial ownership of 8,814,833 shares of common stock, representing 8.1% of the class. The filing, signed May 15, 2026, attributes 1,314,733 shares to TD Securities (USA) LLC and 7,500,000 shares to Toronto Dominion Bank, with 100 shares held by TD Securities Inc. The statement is jointly filed under Rule 13d-1(k) and includes standard disclaimers of group ownership among the reporting entities.